Current Clinical Trials
A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers. They are also called “participants.” Clinical Trials FAQs.
Find a Clinical Trial
| Therapeutic Area | Condition | Description | |
|---|---|---|---|
| Haematology & Thrombosis |
Hemophilia A | CSL627_3001: An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A. | Learn More |
| Hemophilia B | CSL654_3003: A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B | Learn More | |
| Hemophilia A & B | CSL689_2001: Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors | Terminated | |
| Congenital Fibrinogen Deficiency | BI3023_4003: An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency | Completed | |
| Von Willebrand Disease | CSLCT-BIO-12-83: Study of Voncento® in Subjects With Von Willebrand Disease | Completed | |
| Reversal of acquired coagulation factor deficiency | BE1116_4001: An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding | Learn More | |
| Sickle Cell | CSL200_1001: CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease | Learn More | |
| Cardiovascular and Metabolic | Acute Coronary Syndrome | CSL112_3001: Study to investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) | Learn More |
| Coronary Heart Disease |
CSL112:1001: Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults |
Completed | |
| Immunology and Neurology | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | IgPro20_3004: Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Results |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | IgPro10_5004: Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1) | Learn More | |
| Dermatomyositis (DM) | IgPro20_3007: A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with Dermatomyositis (DM) | Learn More | |
| Pediatric CIDP | IgPro10_4002: Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP | Learn More | |
| Hereditary Angioedema (HAE) | CSL312_2001: A study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) | Learn More | |
| Primary Immune Deficiency (PID) | IgPro20_1001: Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump | Learn More | |
| Primary Immune Deficiency (PID) | IgPro20_4005: Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules | Results | |
| Primary Immune Deficiency (PID) | IgPro20_4004: Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra®) in Subjects With Primary Immunodeficiency (PID) | Completed | |
| Healthy Subjects | CSL730_1001: Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults | Learn More | |
| Healthy Subjects | CSL324_1001: Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults | Completed | |
| Respiratory | Mild Asthma | CSL311_1001: A Clinical Study to test the safety, exposure, and markers of Efficacy of CSL311 in patients with mild asthma. | Learn More |
| Transplant | Antibody-mediated kidney transplant rejection | CSL842_3001: Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients | Learn More |
| Acute GVHD (aGVHD) | CSL964_2001: The Safety and Efficacy of Alpha 1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE) | Learn More |
Get our latest news in your inbox
Thanks!
Thank you for subscribing
to the CSL newsletter